Cargando…
Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice
OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to Ju...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023076/ https://www.ncbi.nlm.nih.gov/pubmed/29584537 http://dx.doi.org/10.1177/0300060518757640 |
_version_ | 1783335789778698240 |
---|---|
author | Xia, Jun Wang, Lingling Zhou, Xin Wang, Jing Wang, Huan Guo, Hongfeng |
author_facet | Xia, Jun Wang, Lingling Zhou, Xin Wang, Jing Wang, Huan Guo, Hongfeng |
author_sort | Xia, Jun |
collection | PubMed |
description | OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. RESULTS: EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. CONCLUSION: Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes. |
format | Online Article Text |
id | pubmed-6023076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-60230762018-07-05 Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice Xia, Jun Wang, Lingling Zhou, Xin Wang, Jing Wang, Huan Guo, Hongfeng J Int Med Res Clinical Research Reports OBJECTIVES: This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. METHODS: Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. RESULTS: EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of ≥75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. CONCLUSION: Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of ≥75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes. SAGE Publications 2018-03-27 2018-06 /pmc/articles/PMC6023076/ /pubmed/29584537 http://dx.doi.org/10.1177/0300060518757640 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Clinical Research Reports Xia, Jun Wang, Lingling Zhou, Xin Wang, Jing Wang, Huan Guo, Hongfeng Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title_full | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title_fullStr | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title_full_unstemmed | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title_short | Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
title_sort | early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice |
topic | Clinical Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023076/ https://www.ncbi.nlm.nih.gov/pubmed/29584537 http://dx.doi.org/10.1177/0300060518757640 |
work_keys_str_mv | AT xiajun earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT wanglingling earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT zhouxin earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT wangjing earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT wanghuan earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice AT guohongfeng earlymortalityinelderlypatientsundergoingtreatmentformultiplemyelomainrealworldpractice |